A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Clinical trial NCT01234857 · COMPLETED
Trial details
- NCT number
- NCT01234857
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-17
- Primary completion
- 2013-10-15
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.